Propanc Biopharma (PPCB) Rent Expense (2010 - 2025)
Propanc Biopharma (PPCB) posted quarterly Rent Expense of $6600.0 for Q4 2025, up 22.2% year-over-year from $5401.0 in Q4 2024, and down 55.37% quarter-over-quarter from $14789.0 in Q3 2025.
Propanc Biopharma (PPCB) Rent Expense (2010 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Rent Expense for 11 consecutive years, with $6600.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Rent Expense rose 22.2% year-over-year to $6600.0; the TTM figure through Dec 2025 stood at $34231.0 (down 1.81% YoY), while the FY2025 annual figure was $26560.0, down 22.23% from the prior year.
- Rent Expense declined to $6600.0 in Q4 2025 per PPCB's latest filing, from $14789.0 in the prior quarter.
- Across five years, Rent Expense topped out at $14789.0 in Q3 2025 and bottomed at $1927.0 in Q2 2021.
- Historically, Rent Expense has averaged $7523.2 across 5 years, with a median of $6598.5 in 2023.
- Annual changes were most pronounced in 2021 — Rent Expense sank 72.45% — and 2022, when it soared 207.37%.
- Propanc Biopharma's Rent Expense stood at $6550.0 in 2021, then advanced by 14.6% to $7506.0 in 2022, then decreased by 21.97% to $5857.0 in 2023, then retreated by 7.79% to $5401.0 in 2024, then increased by 22.2% to $6600.0 in 2025.
- Business Quant data shows PPCB's Rent Expense at $6600.0 in Q4 2025, $14789.0 in Q3 2025, and $6373.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Rental Exp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - | - |
| 10 | Propanc Biopharma | 593,787.37 | 593,787.37 | - | 6,600.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6,600.00 |
| Dec 31, 2025 | 6,600.00 |
| Sep 30, 2025 | 14,789.00 |
| Sep 30, 2025 | 14,789.00 |
| Jun 30, 2025 | 6,373.00 |
| Jun 30, 2025 | 6,373.00 |
| Mar 31, 2025 | 6,469.00 |
| Mar 31, 2025 | 6,469.00 |
| Dec 31, 2024 | 5,401.00 |
| Dec 31, 2024 | 5,401.00 |
| Sep 30, 2024 | 8,317.00 |
| Sep 30, 2024 | 8,317.00 |
| Jun 30, 2024 | 14,566.00 |
| Jun 30, 2024 | 14,566.00 |
| Mar 31, 2024 | 6,578.00 |
| Mar 31, 2024 | 6,578.00 |
| Dec 31, 2023 | 5,857.00 |
| Dec 31, 2023 | 5,857.00 |
| Sep 30, 2023 | 7,149.00 |
| Sep 30, 2023 | 7,149.00 |